Loading...
XTAI
1795
Market cap1.67bUSD
Jul 09, Last price  
204.00TWD
1D
-2.63%
1Q
-5.34%
Jan 2017
240.57%
IPO
1,037.12%
Name

Lotus Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XTAI:1795 chart
P/E
11.36
P/S
2.61
EPS
17.96
Div Yield, %
2.83%
Shrs. gr., 5y
1.45%
Rev. gr., 5y
13.84%
Revenues
20.51b
+10.36%
606,822,000590,184,000532,209,000503,153,000658,481,0002,310,021,0005,521,937,0005,902,566,0006,423,760,0006,428,894,0009,174,740,00010,728,583,00012,649,189,00014,632,772,00016,957,971,00018,584,227,00020,509,474,000
Net income
4.72b
-6.82%
3,117,00015,051,000-38,403,000-193,234,00011,882,000-442,127,000103,949,000-134,041,0007,685,00099,476,000662,807,0001,026,796,0001,403,371,0003,020,757,0004,105,626,0005,065,510,0004,720,053,000
CFO
7.48b
+21.56%
89,499,00059,194,000-76,294,000-54,453,000-95,837,000-1,032,408,0001,077,573,0001,233,001,000592,293,000796,978,000302,809,0001,948,682,000119,662,0003,719,418,0001,614,207,0006,154,866,0007,481,979,000
Dividend
Aug 11, 20255.77859 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Lotus Pharmaceutical Co., Ltd. operates as a pharmaceutical enterprise, specializing in the research, development, production, and sale of generic medicines. Its market presence extends across Taiwan, South Korea, the United States, and other global territories. The company primarily targets therapeutic areas such as oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system conditions with its generic product line. In addition to prescription generics, Lotus also offers a diverse array of over-the-counter drugs. Diversifying its business activities, the firm engages in the wholesale distribution of cosmetics, the retail of specialized clinical equipment, and provides biotechnology consulting. It also handles the sale of pharmaceuticals and medicinal chemicals, conducts marketing campaigns, offers market planning and business intelligence services, and provides advisory on health management and health technology. Furthermore, Lotus delivers a suite of services including project management for pharmaceutical regulatory compliance, data collection, and agency functions. It also operates as a healthcare consultancy and a Contract Research Organization (CRO). Established in 1966, Lotus Pharmaceutical Co., Ltd. maintains its principal office in Taipei City, Taiwan. The company is a subsidiary of Alvogen Emerging Markets Holdings Limited.
IPO date
Dec 13, 2004
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT